Parisa Malekzadeh, M.D.
Surgical Oncologist
4.9 (112 RATINGS)
Clinical Expertise
- Surgical Oncology
Academic Appointments
- Assistant Clinical Professor, Division of Surgical Oncology, Department of Surgery
Clinical Teams
Surgery
Breast Cancer
Stomach (Gastric) Cancer
Gastrointestinal Cancers
As assistant clinical professor of surgical oncology at City of Hope® locations in Corona and Upland, Parisa Malekzadeh, M.D., offers patients access to innovative, often minimally invasive, surgical treatments for a wide range of diseases, including skin cancer, stomach cancer, gastrointestinal and breast cancers. Her philosophy when working with patients is centered on respect and collaboration, and she’s committed to fostering a supportive environment where patients feel empowered to self-advocate and participate in their own care.
After earning her medical degree at the University of Arizona College of Medicine in Tucson, Arizona, Dr. Malekzadeh completed a surgical internship and two surgical residencies at Eastern Virginia Medical School in Norfolk, Virginia. She also completed a research fellowship in tumor immunobiology and immunotherapy at the National Cancer Institute’s Surgery Branch and a complex surgical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City.
She has published articles in several peer-reviewed journals, including the Journal of Clinical Investigation and Clinical Cancer Research, and is pursuing research in fields such as immunotherapy, T cell therapies and clinical trial design.
Education & Experience
Degrees
- 2013, M.D., University of Arizona College of Medicine, Tucson, Arizona
Fellowship
- 2024, Complex General Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
- 2019, Surgical Oncology, Tumor Immunobiology and Immunotherapy, National Cancer Institute, Surgery Branch, Bethesda, Maryland
Residency
- 2022, Surgery, Eastern Virginia Medical School, Norfolk, Virginia
- 2015, Surgery, Eastern Virginia Medical School, Norfolk, Virginia
Internship
- 2014, Surgery, Eastern Virginia Medical School, Norfolk, Virginia
Professional Experience
- 2024–Present, Assistant Clinical Professor, Division of Surgical Oncology, Department of Surgery, City of Hope, Corona & Upland, California
Awards & Memberships
Awards
- 2019, Society of Surgical Oncology
- 2019, Harvey Baker Traveling Fellow Award Recipient, March
- 2010–2013, University of Arizona College of Medicine Hill Endowed Scholarship Recipient
- 2011, University of Arizona Community Service Award
- 2010, University of Arizona College of Medicine Class Representative Leadership Award
- 2010, Pima County Medical Society Leadership Award
- 2009, Arizona State University SOLUR Fellow: Independent Undergraduate Research
- 2006–2009, Barret Honors College/Arizona State University College of Liberal Arts and Sciences Deans List
- 2006–2009, Arizona State University Adelante Foundation Scholarship Recipient
- 2006–2007, Arizona State University First Generation College Attendee Scholarship
- 2005, Phoenix Suns Charity Scholarship Recipient
Memberships
- 2023–Present, Association of Women Surgeons Surgical Mentorship Program
- 2022– Present, Society of Surgical Oncology Fellow Member
- 2017–2022, Society of Surgical Oncology Resident Member
- 2014–2022, American College of Surgeons Resident Member
- 2011–2013, American College of Surgeons Medical Student Member
- 2009–2013, American Medical Association (AMA) Medical Student Section
Publications
- Malekzadeh P, Brady SM. What’s new in Surgical Oncology: Adjuvant therapy for Stage 2B and 2C melanoma. Journal Of Surgical Oncology. January 2024. J Surg Oncol. 2024 PMID: 38031847
- Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, Gartner JJ, Sindiri S, Malekzadeh P, Deniger DC, Rosenberg SA, et al. Adoptive cellular therapy with autologous tumor-infiltrating lymphocytes and t cell receptor-engineered t cells targeting common p53 neoantigens in human solid tumors. Cancer Immunol Res. 2022 Aug 3;10(8):932-946, PMID: 35749374
- Kishton RJ, Patel SJ, Decker AE, Vodnala SK, Cam M, Yamamoto TN, Patel Y, Sukumar M, Yu Z, Ji M, Henning AN, Gurusamy D, Palmer DC, Stefanescu RA, Girvin AT, Lo W, Pasetto A, Malekzadeh P, Deniger DC, Wood KC, Sanjana NE, Restifo NP. Cancer genes disfavoring t cell immunity identified via integrated systems approach. Cell Rep. 2022 Aug 2;40(5):111153, PMID: 35926468
- Palmer DC, Webber BR, Patel Y, Johnson MJ, Kariya CM, Lahr WS, Parkhurst MR, Gartner JJ, Prickett TD, Lowery FJ, Kishton RJ, Gurusamy D, Franco Z, Vodnala SK, Diers MD, Wolf NK, Slipek NJ, McKenna DH, Sumstad D, Viney L, Henley T, Bürckstümmer T, Baker O, Hu Y, Yan C, Meerzaman D, Padhan K, Lo W, Malekzadeh P, Rosenberg SA, Restifo NP, et al. Internal checkpoint regulates t cell 2 neoantigen reactivity and susceptibility to pd1 blockade. Med. 2022 Aug 2;40(5):111153, PMID: 36007524
- Malekzadeh P, Good M, Hughes MB. Cytoreductive surgery and hyperthermic intraoperative chemotherapy (hipec) with cisplatin in pediatric patients with peritoneal mesothelioma: a single institution experience and long term follow up. journal of hyperthermia. 2021;38(1):326-331, PMID: 34139940
- Malekzadeh P, Cowan K, Steinberg SM, Camphausen KA, Shriver C, Merino MJ, Good ML, Berman A, Danforth DN. Twenty-five year follow up of a prospective randomized trial comparing preoperative vs postoperative flac/granulocyte-colony-stimulating factor chemotherapy for stage ii breast cancer. American Journal of Clinical Oncology. 2020 May;43(5):334-339, PMID: 32000167
- Good ML, Malekzadeh P, Kriley I, Hernandez JM, Davis JL. Intrahepatic cholangiocarcinoma as a rare secondary malignancy after hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia: case report. Pediatric Transplantation. 2020 Mar;24(2):e13653, PMID: 31944498
- Good ML, Malekzadeh P, Ruff S, Gupta S, Copeland A, Pacak K, Nilubol N, Kebebew E, Patel D. Surgical resection of pheochromocytomas and paragangliomas improves cholesterol levels. World Journal of Surgery. 2020 Feb;44(2):552-560, PMID: 31531722
- Good M, Vicardo R, Maeda T, Tamaoki N, Naritaka T, Malekzadeh P, Kawamoto H, Restifo N. Using human induced pluripotent stem cells for the generation of tumor antigen-specific t cells. JoVE. 2019 Oct 24;(152), PMID: 31710026
- Parkhurst M, Robbins P, Tran E, Prickett T, Gartner J, Jia L, Ivey G, Li Y, El-Gamil M, Lalani A, Crystal J, Sachs A, Groh E, Ray S, Ngo L, Kivitz S, Pasetto A, Yossef R, Lowery F, Goff S, Lo W, Cafri G, Deniger DC, Malekzadeh P, Rosenberg SA, et al. Unique neoantigens arise from somatic mutations in patients with gastrointestinal cancers. Cancer Discovery. 2019 Aug;9(8):1022-1035, PMID: 31164343
- Lo W, Parkhurst M, Robbins PF, Tran E, Lu YC, Jia L, Gartner JJ, Pasetto A, Deniger D, Malekzadeh P, Rosenberg SA, et al. Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol Res. 2019 Apr;7(4):534-543, PMID: 30709841
- Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC, Jia L, Gartner JJ, Hill V, Yu Z, Rosenberg SA, Deniger DC, et al. Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. Journal Clinical Investigation. 2019 Mar 1;129(3):1109-1114, PMID: 30714987
- Malekzadeh P, Yossef R, Cafri G, Paria BC, Rosenberg SA, Deniger DC et al. Antigen experienced T cells from peripheral blood recognize p53 neoantigens. Clinical Cancer Research. 2019 Mar 1;129(3):1109-1114, PMID: 31996390
- Ruff SM, Ayabe RI, Malekzadeh P, Good ML, Wach MM, Gonzales MK, Tirosh A, Nilubol N, Pacak K, Kebebew E, Patel D. MicroRNA-210 may be a preoperative biomarker of malignant pheochromocytomas and paragangliomas. J Surg Res. 2019 May 27;243:1-7. PMID: 31146085
- Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA. Pilot trial of adoptive transfer of chimeric antigen receptor-transduced t cells targeting EGFRvIII in patients with glioblastoma. J Immunother. 2019 May;42(4):126-135. PMID: 30882547
- Mehta GU, Malekzadeh P, Shelton T, White DE, Butman JA, Yang JC, Kammula US, Goff SL, Rosenberg SA, Sherry RM. Outcomes of adoptive cell transfer with tumor-infiltrating lymphocytes for metastatic melanoma patients with and without brain metastases. J Immunother. 2018 Jun;41(5):241-247, PMID: 29672342
- Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, Malekzadeh P, Jia L, Yossef R, Langhan MM, Rosenberg SA, et al. T cell responses to tp53 "hotspot" mutations and unique neoantigens expressed by human ovarian cancers. Clin Cancer Res. 2018 Nov 15;24(22):5562-5573, PMID: 29853601
Ratings & Reviews
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Show respect for what you say
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Spend enough time with you
4.8
Know important info medical history
4.8
Rate provider 0-10
04/24/26
Dr. Malekzadeh is very nice, always explains things and answers my question so I understand them. - Verified patient
04/22/26
We had previously discussed options other than surgery for my atypical cells in my breast such as risk reducing medications and she was to look into clinical trials- this was on her initial report after I met with her. The telemed visit was a follow up to an in person visit. She ordered a new mammogram which was unnecessary as I had already told her the breast calcifications were not all removed so of course they would still show on a new mammogram and an MRI that was benign. She suggested surgery on the telemed call which was not discussed prior and a more major one that [...] had discussed again although my biopsy was benign and MRI was benign and I was very disappointed. She seemed to forget she had mentioned she was going to a conference and would ask about clinical trials. Instead she just relied on the 1st opinion I had from [...]. - Verified patient
03/28/26
Very good - Verified patient
03/28/26
Very good - Verified patient
03/28/26
Very good - Verified patient